[1]王 娟,汪 奎,牛彩琴.贝利木单抗治疗系统性红斑狼疮的有效性和安全性的系统评价[J].医学信息,2021,34(21):65-68.[doi:10.3969/j.issn.1006-1959.2021.21.016]
　WANG Juan,WANG Kui,NIU Cai-qin.System Analysis of the Efficacy and Safety of Belimumab in the Treatment of Systemic Lupus Erythematosus[J].Medical Information,2021,34(21):65-68.[doi:10.3969/j.issn.1006-1959.2021.21.016]
点击复制

贝利木单抗治疗系统性红斑狼疮的有效性和安全性的系统评价()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年21期
页码:
65-68
栏目:
论著
出版日期:
2021-11-01

文章信息/Info

Title:
System Analysis of the Efficacy and Safety of Belimumab in the Treatment of Systemic Lupus Erythematosus
文章编号:
1006-1959（2021）21-0065-04
作者:
王 娟; 汪 奎; 牛彩琴
（1.川北医学院，四川 南充 637000；2.川北医学院附属医院中医科，四川 南充 637000）
Author(s):
WANG Juan; WANG Kui; NIU Cai-qin
(1.North Sichuan Medical College,Nanchong 637000,Sichuan,China;2.Department of Traditional Chinese Medicine,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,Sichuan,China)
关键词:
贝利木单抗; 系统性红斑狼疮; 严重复燃; 不良事件; 应答者指数
Keywords:
Belizemab; Systemic lupus erythematosus; Severe reburning; Adverse events;  Responder Index
分类号:
R593.24+1
DOI:
10.3969/j.issn.1006-1959.2021.21.016
文献标志码:
A
摘要:
目的 采取荟萃分析系统评价贝利木单抗（belimumab）治疗系统性红斑狼疮（SLE）的有效性和安全性。方法 计算机检索PubMed、The Cochrane Library、EMbase、Web of Science、中国知网（CNKI）、中国生物医学文献数据库（CBM）、维普（VIP）、万方（WANFANG DATA）数据库中有关贝利木单抗治疗SLE的随机对照试验，截止日期2020年5月，以应答者指数（SRI）、严重复燃、不良事件、严重不良事件为研究终点，应用Revman5.3软件进行荟萃分析。结果 共纳入6项研究，共计4786例患者；结果显示：试验组SRI反应率（OR=0.63，95%CI：0.55~0.72，P＜0.00001）高于对照组，试验组严重复燃发生率（RR=0.67，95%CI：0.57~0.78，P＜0.00001）、严重不良事件发生率（RR=0.71，95%CI：0.57~0.89，P=0.003）低于对照组，两组不良事件发生率比较，差异无统计学意义（RR=0.98，95%CI：0.94~1.02，P=0.28）。结论 贝利木单抗可用于治疗SLE，现有证据表明能有效提高SRI的反应率，且减少严重复燃和严重不良事件的发生，安全性较好。
Abstract:
Objective To evaluate the efficacy and safety of belimumab in the treatment of systemic lupus erythematosus (SLE) by Meta-analysis system.Methods We searched PubMed, the Cochrane Library, EMbase, Web of Science, China National Knowledge Infrastructure (CNKI), China Biomedical Literature Database (CBM), VIP, and WANFANG DATA databases for randomized controlled trials of belamab in the treatment of SLE. The deadline was May 2020. The SLE Responder Index (SRI), severe reburning, adverse events, and severe adverse events were used as the endpoints of the study. Revman 5.3 software was used for Meta-analysis.Results A total of 6 studies were included, with a total of 4786 patients. The results showed that the SRI response rate in the experimental group (OR=0.63, 95%CI:0.55-0.72, P<0.00001 ) was higher than that in the control group. The incidence of severe reignition (RR=0.67, 95%CI:0.57-0.78, P<0.00001 ) and the incidence of severe adverse events (RR=0.71, 95%CI:0.57-0.89, P=0.003) in the experimental group were lower than those in the control group. There was no significant difference in the incidence of adverse events between the two groups (RR=0.98, 95%CI:0.94-1.02, P=0.28).Conclusion Belimumab can be used to treat SLE. Existing evidence shows that it can effectively and safely increase the SRI response rate, and reduce the occurrence of serious flare and serious adverse events.

参考文献/References:

[1]中华医学会风湿病学分会,国家皮肤与免疫疾病临床医学研究中心,中国系统性红斑狼疮研究协作组.2020中国系统性红斑狼疮诊疗指南[J].中华内科杂志,2020(3):172-185.[2]杨华夏,张奉春.系统性红斑狼疮新型生物治疗靶点:希望与挑战[J].协和医学杂志,2020,11(3):241-246.[3]Ginzler EM,Wallace DJ,Merrill JT,et al.Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus[J].J Rheumatol,2014,41(2):300-309. [4]Manzi S,Sánchez-Guerrero J,Merrill JT,et al.Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials[J].Ann Rheum Dis,2012,71(11):1833-1838.[5]Stohl W,Schwarting A,Okada M,et al.Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study[J].Arthritis Rheumatol,2017,69(5):1016-1027.[6]Wallace DJ,Stohl W,Furie RA,et al.A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus[J].Arthritis Rheum,2009,61(9):1168-1178.[7]Furie R,Petri M,Zamani O,et al.A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus[J].Arthritis Rheum,2011,63(12):3918-3930.[8]Zhang F,Bae SC,Bass D,et al.A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea[J].Ann Rheum Dis,2018,77(3):355-363.[9]Furie R,Wang L,Illei G,et al.Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE[J].Lupus,2018,27(6):955-962.[10]Nossent J,Kiss E,Rozman B,et al.Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus[J].Lupus,2010,19(8):949-956. [11]贺成美,张奉春.贝利木单克隆抗体:治疗系统性红斑狼疮的新型靶向药物[J].协和医学杂志,2020,11(2):130-134.

相似文献/References:

[1]吴 霞,肖盼盼,谢晓然,等.qRT-PCR法分析复发性SLE患者肠道双歧杆菌、 柔嫩梭菌数量的变化[J].医学信息,2018,31(05):65.[doi:10.3969/j.issn.1006-1959.2018.05.022]
　WU Xia,XIAO Pan-pan,XIE Xiao-ran,et al.Analysis of the Changes of Intestinal Bifidobacterium and Clostridium Tenella in Patients with Recurrent SLE by qRT-PCR[J].Medical Information,2018,31(21):65.[doi:10.3969/j.issn.1006-1959.2018.05.022]
[2]屈佳琪,李 洋.核酸传感器与CD72在系统性红斑狼疮中的作用[J].医学信息,2019,32(14):49.[doi:10.3969/j.issn.1006-1959.2019.14.017]
　QU Jia-qi,LI Yang.The Role of Nucleic Acid Sensors and CD72 in Systemic Lupus Erythematosus[J].Medical Information,2019,32(21):49.[doi:10.3969/j.issn.1006-1959.2019.14.017]
[3]陈汉白,赵之婧,罗希莹,等.系统性红斑狼疮治疗领域文献的大数据分析[J].医学信息,2019,32(23):1.[doi:10.3969/j.issn.1006-1959.2019.23.001]
　CHEN Han-bai,ZHAO Zhi-jing,LUO Xi-ying,et al.Big Data Analysis of Literature in the Field of Systemic Lupus Erythematosus Treatment[J].Medical Information,2019,32(21):1.[doi:10.3969/j.issn.1006-1959.2019.23.001]
[4]白巧红.系统性红斑狼疮合并感染的临床特点[J].医学信息,2019,32(23):86.[doi:10.3969/j.issn.1006-1959.2019.23.023]
　BAI Qiao-hong.Clinical Features of Systemic Lupus Erythematosus Infection[J].Medical Information,2019,32(21):86.[doi:10.3969/j.issn.1006-1959.2019.23.023]
[5]徐 莹,薛国辉,华 琳.系统性红斑狼疮患者中TAFI、PAI-1及t-PA水平变化及其与疾病活动度的关系[J].医学信息,2020,33(20):54.[doi:10.3969/j.issn.1006-1959.2020.20.015]
　XU Ying,XUE Guo-hui,HUA Lin.Changes of TAFI,PAI-1 and t-PA Levels in Patients with Systemic Lupus Erythematosus and Their Relationship with Disease Activity[J].Medical Information,2020,33(21):54.[doi:10.3969/j.issn.1006-1959.2020.20.015]
[6]皮玲玲.基于Medline数据库的国内风湿病发表论文的可视化分析[J].医学信息,2022,35(03):13.[doi:10.3969/j.issn.1006-1959.2022.03.003]
　PI Ling-ling.Visual Analysis of Published Papers on Rheumatism in China Based on Medline Database[J].Medical Information,2022,35(21):13.[doi:10.3969/j.issn.1006-1959.2022.03.003]
[7]卢 慧,钱 龙.淋巴细胞亚群与系统性红斑狼疮患者发生感染的相关性[J].医学信息,2022,35(04):111.[doi:10.3969/j.issn.1006-1959.2022.04.027]
　LU Hui,QIAN Long.Correlation Between Lymphocyte Subsets and Infection in Patientswith Systemic Lupus Erythematosus[J].Medical Information,2022,35(21):111.[doi:10.3969/j.issn.1006-1959.2022.04.027]

更新日期/Last Update: 1900-01-01